GoodRx (NASDAQ:GDRX) Shares Gap Down – Time to Sell?

Shares of GoodRx Holdings, Inc. (NASDAQ:GDRX) gapped down before the market opened on Friday . The stock had previously closed at $4.95, but opened at $4.81. GoodRx shares last traded at $4.81, with a volume of 131,259 shares trading hands.

Analyst Ratings Changes

A number of research firms have recently issued reports on GDRX. Citigroup reduced their price target on shares of GoodRx from $7.00 to $6.25 and set a “buy” rating on the stock in a research report on Friday, January 10th. KeyCorp lowered their target price on GoodRx from $7.00 to $6.00 and set an “overweight” rating for the company in a report on Wednesday, January 8th. Mizuho initiated coverage on GoodRx in a report on Wednesday, December 4th. They issued a “neutral” rating and a $5.00 price target on the stock. Morgan Stanley lowered their price objective on GoodRx from $7.00 to $6.00 and set an “equal weight” rating for the company in a research note on Tuesday, December 17th. Finally, Barclays cut their target price on GoodRx from $10.00 to $6.00 and set an “overweight” rating on the stock in a research note on Monday, November 11th. Five equities research analysts have rated the stock with a hold rating, nine have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $8.38.

GoodRx Price Performance

The company has a market cap of $1.86 billion, a price-to-earnings ratio of -161.70, a PEG ratio of 2.45 and a beta of 1.27. The company’s 50 day moving average price is $4.66 and its 200-day moving average price is $6.26. The company has a debt-to-equity ratio of 0.70, a quick ratio of 5.48 and a current ratio of 5.48.

Institutional Investors Weigh In On GoodRx

Several hedge funds have recently made changes to their positions in GDRX. Fortem Financial Group LLC acquired a new stake in shares of GoodRx during the third quarter worth approximately $772,000. Barclays PLC increased its stake in shares of GoodRx by 1,316.1% in the third quarter. Barclays PLC now owns 140,113 shares of the company’s stock worth $973,000 after acquiring an additional 130,219 shares during the last quarter. Charles Schwab Investment Management Inc. raised its holdings in shares of GoodRx by 5.8% during the third quarter. Charles Schwab Investment Management Inc. now owns 480,123 shares of the company’s stock worth $3,332,000 after acquiring an additional 26,262 shares in the last quarter. Raymond James & Associates boosted its position in GoodRx by 212.6% during the third quarter. Raymond James & Associates now owns 394,006 shares of the company’s stock valued at $2,734,000 after purchasing an additional 267,951 shares during the last quarter. Finally, Dynamic Technology Lab Private Ltd increased its position in GoodRx by 260.7% in the 3rd quarter. Dynamic Technology Lab Private Ltd now owns 44,419 shares of the company’s stock worth $308,000 after purchasing an additional 32,104 shares during the last quarter. Hedge funds and other institutional investors own 63.77% of the company’s stock.

About GoodRx

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.